FoxP3 expression in luminal A, luminal B, HER2 overexpressors and Triple Negative Breast Cancers (TNBC): A clinical & immunohistochemical correlation study

被引：0
|
作者：
Vidak, J. [1 ]
Ali, N. [1 ]
Trivedi, P. [1 ]
Ramakrishnan, R. [1 ]
机构：
[1] St Marys Hosp, Dept Cytopathol, London, England
来源：
VIRCHOWS ARCHIV | 2013年 / 463卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [1] Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
    Atallah, Nehal M.
    Haque, Maria
    Quinn, Cecily
    Toss, Michael S.
    Makhlouf, Shorouk
    Ibrahim, Asmaa
    Green, Andrew R.
    Alsaleem, Mansour
    Rutland, Catrin S.
    Allegrucci, Cinzia
    Mongan, Nigel P.
    Rakha, Emad
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [2] Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC)
    Lee, S.
    Park, Y. H.
    Cho, E. Y.
    Ham, Y. H.
    Seo, J. J.
    Ahn, J. S.
    Im, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings
    Hashmi, Atif A.
    Bukhari, Ummara
    Najam, Javeria
    Dowlah, Tanim
    Ali, Abrahim H.
    Diwan, Muhammad Asad
    Anjali, Fnu
    Sham, Sunder
    Zia, Shamail
    Irfan, Muhammad
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
  • [4] Glucocorticoid receptors are expressed in diverse molecular subtypes of breast cancer and in peri tumoral stroma: luminal A, luminal B HER plus , luminal B HER-, and triple-negative breast cancers
    Buxant, F.
    Kindt, N.
    Gubana, F.
    Catteau, X.
    Journe, F.
    Saussez, S.
    Noel, J-C.
    [J]. BREAST, 2019, 44 : S31 - S31
  • [5] Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
    Masumi Yanagawa
    Kenzo Ikemot
    Shigeto Kawauchi
    Tomoko Furuya
    Shigeru Yamamoto
    Masaaki Oka
    Atunori Oga
    Yukiko Nagashima
    Kohsuke Sasaki
    [J]. BMC Research Notes, 5 (1)
  • [6] How Luminal Are Triple Negative Breast Cancers? A Cytokeratin Co-Expression Study
    Oprea-Ilies, G. M.
    Liu, Y.
    Nickleach, D.
    Mclendon, L. A.
    Pambuccian, S. E.
    [J]. MODERN PATHOLOGY, 2013, 26 : 60A - 61A
  • [7] Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer
    Rajc, Jasmina
    Gugic, Damir
    Frohlich, Irena
    Marjanovic, Ksenija
    Dumencic, Boris
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (09) : 1102 - 1108
  • [8] How Luminal Are Triple Negative Breast Cancers? A Cytokeratin Co-Expression Study
    Oprea-Ilies, G. M.
    Liu, Y.
    Nickleach, D.
    Mclendon, L. A.
    Pambuccian, S. E.
    [J]. LABORATORY INVESTIGATION, 2013, 93 : 60A - 61A
  • [9] Mammographic findings in different breast cancer subtypes (luminal, Her2 positive, triple negative)
    Pourali, L.
    Sales, S. Shahid
    Taghizadeh, A.
    Pezeshkirad, M.
    Farokh, D.
    Andakhshideh, E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2018, 16 (02): : 251 - 255
  • [10] An easy and practical prognostic parameter: tumor-stroma ratio in Luminal, Her2, and triple-negative breast cancers
    Ozturk, Cigdem
    Okcu, Oguzhan
    Sen, Bayram
    Bedir, Recep
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2022, 68 (02): : 227 - 233
12345